| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| ROBINS CHAD M | CEO and Chairman, Director | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVENUE EAST, SEATTLE | /s/ Chad M Robins by Kyle Piskel, Attorney-in-Fact | 13 Mar 2026 | 0001780649 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ADPT | Common Stock | Sale | $1,851,267 | -140,567 | -5.1% | $13.17 | 2,630,713 | 11 Mar 2026 | Direct | F1 |
| transaction | ADPT | Common Stock | Sale | $4,340,832 | -329,600 | -13% | $13.17 | 2,301,113 | 11 Mar 2026 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. |
| F2 | This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance share units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. |